Exploring the mechanism of Tengli Kangliu Decoction in the prevention and treatment of colorectal cancer precancerous based on network pharmacology

Fang Liu, MDa,b, Bo Caoa, Heng Zhang1,b, Qi Zou, MDa,b, Guoxiong Liud, Yukun Dongc, Dan Sua,b,*
Dong-lin Ren, MDa,b,*

Abstract

Objective: This study aimed to predict the targets and signaling pathways affected by Tengli Kangliu Decoction (TKD) in the treatment of colorectal cancer (CRC) precursor lesions and to determine TKDs mechanism of action based on previous experimental results using network pharmacology techniques and methods.

Methods: Using the traditional Chinese medicine systems pharmacology database (TCMSP) and UniProt database, the active ingredients and potential targets of TKD were identified. Human colorectal adenoma (CRA) targets were analyzed using the GeneCards database, the Online mendelian inheritance in man (OMIM) database, and the NCBI database. The common targets of drug-disease interactions were input into the String database to construct a protein–protein interaction (PPI) network. These data were then used to construct the network diagram. Gene ontology (GO) function analysis and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis were performed on the target genes. Finally, the component-disease-pathway-target network file was imported into Cytoscape 3.8.0 and used to construct the pathway network diagram.

Results: Compounds with a drug-likeness (DL) score ≥ 0.18 and an oral bioavailability (OB) ≥ 30% were selected as the active constituents of TKD. Two hundred eighty eight chemical constituents were screened and 305 chemical drug targets were predicted. After further screening, 1942 disease-related targets, which are hypothesized to be the main chemical components of TKD, were obtained. When comparing the targets of action and CRA treatment targets, 172 common targets were identified. Using GO enrichment analysis of common targets of drug diseases, 2550 biological processes (BP) were predicted, 164 items of which were related to molecular functioning (MF), and 67 items related to cell composition. KEGG pathway analysis was performed on the common targets of drug diseases, and a total of 178 signaling pathways were enriched.

Conclusion: Using network pharmacology research, this study reports on the synergistic effect of the multiple components of TKD on the multi-target, and multiple pathways of colorectal precancerous lesions. These findings lay a theoretical foundation for further colorectal precancerous lesions research.

Abbreviations: BP = biological processes, CRA = colorectal adenoma, CRC = colorectal cancer, DL = drug-likeness, GO = gene ontology, KEGG = Kyoto encyclopedia of genes and genomes, MCODE = molecular complex detection, MF = molecular functioning, OB = oral bioavailability, OMIM = Online mendelian inheritance in man, PPI = protein–protein interaction, TCMSP = traditional Chinese medicine systems pharmacology database, TKD = Tengli Kangliu Decoction.

Keywords: colorectal adenomas, network pharmacology, precancerous lesions, Tengli Kangliu Decoction

FL and BC contributed equally to this work.

This study was supported by the Funds for Guiyang Science and technology project (Zhu Ke He Tong[2019]9-2-18); The project of Guizhou Administration of Traditional Chinese Medicine(QZYY2017-105); Project supported by Guizhou University of Traditional Chinese Medicine (Gui Zhong Yi Ke Yuan Nei [2017]01).

The authors have no conflict of interests to disclose.

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

* Correspondence: Dan Su and Dong-Lin Ren, Department of Coloproctology, The Sixth Affiliated Hospital, Sun Yat-sen University, 26 Yuancun Erheng Road, Guangzhou 510655, China. E-mails: sudan3@mail.sysu.edu.cn; rendl@mail.sysu.edu.cn.

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. How to cite this article: Liu F, Cao B, Zhang H, Zou Q, Liu G, Dong Y, Su D, Ren D-I. Exploring the mechanism of Tengli Kangliu Decoction in the prevention and treatment of colorectal cancer precancerous based on network pharmacology. Medicine 2022;101(46):e31690.

Received: 27 May 2022 / Received in final form: 16 October 2022 / Accepted: 17 October 2022

http://dx.doi.org/10.1097/MD.0000000000031690
1. Introduction
Colorectal cancer (CRC) is a serious threat to human health and survival. In recent years, the incidence of CRC is on the rise. Further, CRC research is a hotspot that attempts to provide solutions to difficulties experienced in the medical field. In the United States alone, approximately 150,000 patients were diagnosed with CRC in 2019, of which, approximately 50,000 died due to tumor progression.[1] Globally, CRC is the third most common malignant tumor and the second leading cause of cancer death.[2] In 2021, in the United States, the incidence of CRC accounted for 8% of the cancer cases, with a similar incidence and mortality observed in men and women.[3] The pathology and development of CRC is a continuous and progressive process (Fig. 1A). A colorectal adenoma (CRA) is recognized as a precancerous lesion of colon cancer. Relevant data indicate that more than 90% of CRC can develop from a colonic polyp, among which, CRA has a higher risk of malignancy.[4,5] It takes 5 to 10 years for a CRA to develop into CRC. Therefore, the prevention and treatment of clinically active CRA are of great significance to prevent the occurrence and development of CRC.

The idea of “preventing disease” in traditional Chinese medicine (TCM) agrees with the idea of disease prevention in western medicine; both of which have shown great value in the prevention and control of CRC. Previous studies have shown that TCM has great advantages in the prevention and control of colorectal precancerous lesions and reducing the incidence of CRC based on the theoretical guidance of prevention before disease.[6] The effect of traditional Chinese medicine on colorectal precancerous lesions is mainly due to its multi-component, multi-target, and multi-channel synergistic activity. Thus, through multi-channel, multi-step, and multi-stage intervention it may be possible to inhibit or delay the onset of cancer.

Based on the concept of “disease-gene-target-drug” multi-level and multi-angle interaction networks, network pharmacology is a new strategy used to study the multi-molecule synergistic effects of traditional Chinese medicine ingredient-targets interactions at the system level. The concept of systematically and comprehensively observing the intervention and influence of drugs on disease networks has been widely used in the study of traditional Chinese medicine mechanisms. Previously, we showed that “Tengli Kangliu Decoction” (TKD), a traditional Chinese medicinal concoction, has a significant beneficial effect in the treatment of colorectal precancerous lesions[7] (Fig. 1B); however, the mechanism of action was unclear. Therefore, based on previous network pharmacology experiments, the current study aims to further explore the mechanism of TKD on precancerous lesions of CRC.

2. Materials and methods

2.1. Screening of the active ingredients and corresponding targets of TKD
The active ingredients and their corresponding targets of TKD were obtained from the database of Traditional Chinese Medicine system pharmacology (TCMSP,http://tcmspw.com/tcmsp.php).[8] Using “Tengligen,” “Baihuasheshcao,” “Banzhilian,” “Chenpi,” “Chishao,” “Danshen,” “Danggui,” “Dangshen,” “Fuling,” “Fuzi,” “Huangqi,” “Jiezi,” “Shanzha,” “Shanzhuyu,” “Shudi,” “Tusizi,” “Wumei,” “Wuweizi,” and “Zexie” as the keywords, data pertaining to the active ingredients of TKD were retrieved and screened by the pharmacokinetic parameters. According to the recommendations detailed by the TCMSP, the oral bioavailability (OB) and drug-likeness (DL) values were used as the indexes for screening the compounds of TKD. Compounds with DL ≥ 0.18 and OB ≥ 30% were selected

Figure 1. (A) The development of colorectal cancer (CRC). (B) The effect of Tengli Kangliu Decoction (TKD) on prevention and treatment of colorectal adenomas (CRA).
as the active constituents of TKD. Further, the CNKI database (1989-2021) was used to supplement and improve these findings. Based on the Mol ID of the ingredients in the TCMSP database, potential protein targets of chemical constituents were predicted. Using the UniProt database (https://www.uniprot.org/), the chemical component target protein name target name was used to identify the corresponding gene name.

2.2. Screening and sorting of CRA targets

Using “colorectal adenoma” and “colorectal adenomas” as the keywords to interrogate the GeneCards database[10] database (https://www.genecards.org/), the online mendelian inheritance in man (OMIM) database[11] (https://www.omim.org/), and the NCBI database[12] (https://www.ncbi.nlm.nih.gov), gene targets for human adenoma were assessed. The target score of the results retrieved from the GeneCards database was screened using the median value to obtain more relevant targets.

2.3. Target prediction of TKD in the treatment of CRA

The screened drug target data and disease target data were imported into the Venny 2.1 software package, and a Venn diagram was drawn. The intersection of the drug-target and disease-target data was used to obtain common targets, which was then used to predict the drug target of CRC.

2.4. Protein–protein interaction (PPI) network construction and key targets screening

The common targets of TKD and CRA were inputted into the String database[13] (https://string-db.org/cgi/input.pl) and used for the construction of the Protein-Protein interaction network. The species was set as “Homo sapiens” and a confidence interval > 0.7 was used to generate the PPI network. The PPI network was then imported into Cytoscape 3.8.0. Using the NetworkAnalyzer tool to perform topological analysis, targets were sorted by degree, and those with a score greater than the average score were determined as key targets. Key targets were then screened by molecular complex detection (MCODE) analysis.[15] The constructed PPI network was imported into Cytoscape 3.8.0, and the MCODE module was used for target cluster analysis and core target screening. To better understand the complex interaction between components, diseases, and corresponding targets, the component-disease-target network diagram was constructed.

2.5. Gene ontology (GO) enrichment analysis and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis

The common targets of the drug-disease interaction as enriched by GO analysis included those involved in biological processes (BP), molecular functioning (MF), and cell components (CC). These targets were selected by referencing the String database and correcting the P-value < .05. KEGG enrichment analysis was utilized to assess signaling pathways enriched by the common targets of TKD and CRA. By referring to the String database, items with P-value < .05 were screened using R 4.0.3 software. Specifically, the clusterProfiler, enrichplot, and ggplot2 packages were used to generate histograms and bubble charts.

2.6. Composition-disease-pathway-target network construction

The component-disease-pathway-target network file was imported into Cytoscape 3.8.0 and the network diagram was constructed. This strategy allowed for a more intuitive explanation of the characteristics of the multi-component-multi-target effect of TCM in the treatment of diseases. The specific design ideas of this study are shown in Figure 2.

3. Results

3.1. Screening and target prediction results of TKD

In this study, targets of the active ingredients of TKD were predicted using the TCMSP database. The 19 traditional Chinese medicines of TKD were characterized by OB ≥ 30% and DL ≥ 0.18, respectively. A total of 288 compounds were screened. Among them, “Tengligen 6,” “Baihuashexiao 7,” “Banzhilian 29,” “Chenpi 3,” “Chishao 29,” “Danshen 65,” “Danggui 2,” “Dangshen 21,” “Fuling 15,” “Fuzi 21,” “Huangqi 20,” “Jiezi 3,” “Shan-zha 6,” “Shanzhuyu 20,” “Shudi 2,” “Tusizi 11,” “Wumei 8,” “Wuweizi 8,” and “Zexie 10” were identified. The UniProt database was used to retrieve potential target information that corresponded to the active ingredients screened from the TCMSP database. Target gene names were standardized, and a total of 305 targets were predicted after they had been summarized and the [other repetitions genes] had been deleted.

3.2. Results of target screening for CRA

Using the keywords “colorectal adenoma” and “colorectal adenomas,” the GeneCards[10] database (https://www.genecards.org/), OMIM database[11] (https://www.omim.org/), and the NCBI database[12] (https://www.ncbi.nlm.nih.gov/) were searched for human adenoma targets. Using the target scores extracted from the GeneCards database, all potential hits were screened using the median value to obtain more relevant targets. After the removal of duplicates, a total of 1942 disease-related targets were obtained.

3.3. Prediction of therapeutic targets of TKD in patients with CRC

The screened TKD and CRA target data were imported into Venny 2.1. After the two datasets were intersected, 172 predicted targets for TKD were identified (Fig. 3).

3.4. PPI network construction and key target screening results

3.4.1. PPI network construction. To construct the PPI network, the shared targets of TKD and CRA were inputted into the String database. The species was set as Homo sapiens with a reliability score of ≥ 0.7 was used. One hundred seventy two nodes and 1673 edges were observed in the network, and the average degree value was 19.5. Within Figure 4, the PPI network diagram exported from the string website and the PPI network diagram drawn by the Cytoscape software is presented (Fig. 5A and B). The color and size of the nodes in Figure 4B were adjusted according to the degree value. The larger the shape and the intensity of the color indicate a large degree value. The thickness of the line (from thick to thin) indicates large to small
Additionally, the analysis of target clusters and re-screening of core targets was performed using the MCODE module. Using this method, a total of 8 target clusters and 7 core targets were obtained (Fig. 4). The core targets identified were SREBF1, ICAM1, AHR, FOS, SPP1, HIF1A, and PRKCD.

3.5. Component-disease target network construction

To better understand the complex interactions between the medicinal components, CRA, CRC, and the predicted drug targets, the component-disease-target network diagram was constructed (Fig. 6).

3.6. Key component screening

The composition-disease-target network diagram was imported into Cytoscape 3.8.0 for topology analysis and the components were ranked by degree. The higher the degree value was, the more important the components were determined to be (Table 2). Using topological analysis, potential active components within TKD were predicted to be: quercetin, luteolin, kaempferol, wogonin, baicalein, baicalein, isorhamnetin, and sichuan chenpi or citrus peel naringin, etc. The specific compound characteristics and structures are shown in Table 3. These active ingredients may play a relatively important role in the treatment of CRA, (Table 3).

3.7. GO enrichment analysis and KEGG pathway enrichment analysis

3.7.1. GO enrichment analysis. Using GO analysis, a total of 2550 BP were enriched, including 164 hits that were related to MF and 67 items related to cell composition (Fig. 7A and B).

3.7.2. KEGG pathway enrichment analysis. KEGG pathway enrichment analysis was performed on the common target genes of TKD and CRA. Results with a corrected P-value < .05 were screened using the String database and a total of 178 signal pathways were enriched (Table 4 and Fig. 8A and B).
3.8. Composition-disease-pathway-target network construction

The component-disease-pathway-target network file was imported into Cytoscape 3.8.0 and the path network diagram was constructed. This method allows for an intuitive demonstration of the multi-component, multi-pathway, and multi-target function characteristics of TKD active ingredients important in the treatment of CRA (Fig. 9).

4. Discussion

Globally, CRC is a significant contributor to cancer death. Further, due to the lack of effective therapeutic drugs, prevention remains the main strategy to reduce the incidence and mortality. CRC risk can be mitigated by avoiding known factors that increase the chance of developing CRC, or by targeting groups of subjects with a known risk of developing cancer. Early diagnosis of cancer or preneoplastic lesions and secondary
prevention of intervention is essential to preventing the onset of disease.\textsuperscript{[16]} The intervention study of TKD on CRA in this study belongs to the secondary prevention of CRC.

TKD is a prescription for personal experience summarized by Professor Renjie Shi, a famous traditional Chinese medicine doctor in Jiangsu Province. A CRA is a precancerous lesion of CRC with complex etiology. CRC pathogenesis is characterized by condensation or aggregation of phlegm, dampness, blood stasis, and poison due to a deficiency of positive qi. TKD is used for the treatment of several diseases and has heat-clearing, detoxification, and anti-tumor activity. TKD utilizes Tengli as the main medicinal component; however, the medicine is often supplemented with Huangqi, Danggui, Dangshen, Fuzi, Huangqi, Shanzhuyu, Shudi, Tuwesi, Yiqi yangxue, nourishing yin and tonifying yang, and fuzheng Guyuan. Additionally, “Baihuasheshcao,” “Banzhilian,” “Chishao,” “Danshen”jiezi,” and “Wumei” are often used as adjuvants. The medicinal decoction is hypothesized to activate blood circulation, remove blood stasis, play a role in detoxication, activate collaterals, and eliminate stagnation. Further, “Chenpi,” “Fuling,” “Zexie,” “Shanzha are believed to dissolve phlegm and dampness, eliminate lead stagnation, anti-greasy drugs and hinder gas. Together, these drugs strengthen solid yuan, resolving phlegm, dampness and stasis, detoxification, and sanjie. Thus, the same compounds may play a role in the prevention and treatment of CRA. Our previous studies have confirmed that TKD can reduce the recurrence of human CRAs after surgery and inhibit colorectal precancerous lesions in C57BL/6

Table 1

| Name     | Betweenness centrality | Closeness centrality | Clustering coefficient | Degree | Eccentricity | Radiality | Topological coefficient |
|----------|------------------------|----------------------|------------------------|--------|--------------|-----------|-------------------------|
| PTGS2    | 0.04155092             | 0.53594771           | 0.47948718             | 40     | 3            | 0.82682927 | 0.25376712              |
| CXCL8    | 0.01873505             | 0.53074434           | 0.47804878             | 41     | 4            | 0.82317073 | 0.25077293              |
| ESR1     | 0.02541646             | 0.55218855           | 0.38095238             | 43     | 3            | 0.83708488 | 0.22230722              |
| RELA     | 0.00940494             | 0.5448505            | 0.42857143             | 43     | 3            | 0.83292683 | 0.24591452              |
| IL1B     | 0.02002961             | 0.51735016           | 0.43333333             | 45     | 4            | 0.81341463 | 0.24006734              |
| CASP3    | 0.01870111             | 0.55033557           | 0.36666667             | 45     | 3            | 0.83658537 | 0.22906797              |
| MMP9     | 0.03249656             | 0.55218855           | 0.39233671             | 46     | 3            | 0.83708488 | 0.23286745              |
| COND1    | 0.01838555             | 0.54304636           | 0.386679               | 47     | 4            | 0.83107324 | 0.2345154               |
| HSP90AA1 | 0.04440134             | 0.54849498           | 0.2542517              | 49     | 4            | 0.83568583 | 0.19723134              |
| MYC      | 0.02667007             | 0.559322             | 0.37714286             | 50     | 4            | 0.8402439  | 0.2328095               |
| EGFR     | 0.0250921              | 0.5651724            | 0.31843137             | 51     | 4            | 0.84634146 | 0.21181631              |
| STAT3    | 0.02120788             | 0.58165028           | 0.3871483              | 58     | 3            | 0.8509756  | 0.22765426              |
| MAPK3    | 0.02411321             | 0.58571429           | 0.34180278             | 58     | 3            | 0.85853659 | 0.21735354              |
| ILE      | 0.0309283              | 0.59636364           | 0.37652036             | 62     | 3            | 0.86463415 | 0.21789802              |
| TNF      | 0.03628645             | 0.5992906            | 0.35850405             | 62     | 3            | 0.86097561 | 0.21402801              |
| JUN      | 0.02411353             | 0.58781362           | 0.36805923             | 62     | 3            | 0.8597561  | 0.22773697              |
| MAPK8    | 0.03726901             | 0.59205776           | 0.28701923             | 65     | 4            | 0.86219512 | 0.20050942              |
| MAPK1    | 0.04045562             | 0.6119403            | 0.31457801             | 69     | 3            | 0.87317073 | 0.2053841               |
| TP53     | 0.10578016             | 0.64313725           | 0.25308642             | 81     | 3            | 0.88902439 | 0.18067426              |
| AKT1     | 0.1413163              | 0.65863454           | 0.20959693             | 87     | 3            | 0.89634146 | 0.17069712              |

Figure 6. Component-disease target network construction. Note: In the network, the light blue is the active ingredient, the green is the target of the disease, the orange rectangle is the disease, and the purple is the drug.
mice. Together these lines of evidence suggest that TKD may be beneficial in CRC prevention.

In 1959, the use of Teng Ligen in TCM was first published in "Henan Chinese Herbal Medicine Handbook." In the handbook, Teng Ligen roots and root bark are described to be cold in nature and bitter in taste. Teng Ligen is a commonly used CM with anti-tumor activity. Additionally, it is used to clear away heat and for detoxification. It is endemic to and widely distributed throughout China. Modern pharmacological studies have found that the roots of Teng Ligen mainly contain triterpenes, flavonoids, anthraquinones, steroids, and other active ingredients, which have anti-tumor, antioxidant, liver protection, and anti-inflammatory effects. Teng Ligen has a synergistic or even better effect with western medicine. 

In clinical settings, the multi-component, multi-channel, multi-target synergistic effect of traditional Chinese medicine is hypothesized to be better than single-target chemical drugs with large side effects and poor efficacy. However, due to the paucity of sufficiently powered clinical trials as well as convincing mechanistic data, the modernization of Chinese medicine has been impaired. In recent years, the emergence of network pharmacology has provided new insights to clarify the mechanisms of action of traditional Chinese medicine. Network pharmacology is a research method based on "disease-gene-target-protein-drug" interaction networks. This strategy systematically and comprehensively interrogates the intervention and influence of drugs on disease networks, thereby revealing the effect of drugs and target proteins on the disease. Furthermore, in biomedicine, network pharmacology reflects the trend of systematic research in the era of big data and adapts to the urgent need for systematic research methods in traditional Chinese medicine. Therefore, network pharmacology has become a cutting-edge analytical strategy and a hot spot in the field of medicine. This fact is especially true in the field of traditional Chinese medicine research as network pharmacology is expected to be a key tool used to bridge Chinese and Western medicine. Traditional Chinese medicine has a multi-target therapeutic mechanism and has great potential for the treatment of human cancer in the future.

Using PPI network analysis to assess the 10 core targets for drug-diseases interactions, AKT1, TP53, MAPK1, MAPK8, JUN, IL6, TNF, STST3, MAPK3, EGFR, etc. AKT, also known
as protein kinase B (PKB), is a serine/threonine kinase that participates in a variety of important cell signal transduction pathways, including cell survival, proliferation, invasion, apoptosis, and angiogenesis were observed.[24] Akt is a key effector in the PI3K/AKT1 mTOR signaling pathway, and its abnormal regulation plays an important role in the pathogenesis of many human tumors. Akt has three subtypes in mammals: Akt1, Akt2, and Akt3. Akt1 is one of the most frequently mutated subtypes of the AKT protein. Akt1 can inhibit apoptosis and promote cell growth, which not only affects the proliferation and apoptosis of tumor cells but also has an important impact on tumor invasion and metastasis.[25] The TP53 gene is located on the short arm of chromosome 17 (17p13). Previous studies have shown that exons 5-8 are tumor hotspot mutations. The DNA binding domain, encoding exons 5-8 of the TP53 gene, consists of 102-292 residues. In the DNA binding domain, the L2 loop (residues 163-195) and the L3 loop (residues 236-251) bind to the Zn atom and play a key role in DNA interaction. As one of the most common gene mutations[26] in most human tumors, the existence of TP53 gene mutation is often observed. Mitogen-activated protein kinase 1 (MAPK1) is an important protein in MAPK signal transduction. It causes MAPK inactivation by

Figure 7. GO enrichment. GO = gene ontology.
Table 4
The top 20 significant enriched KEGG pathways for intersection target.

| Description                           | P value | Count | GeneID                                                                 |
|---------------------------------------|---------|-------|------------------------------------------------------------------------|
| AGE-RAGE signaling pathway in diabetic complications | 3.53E-38 | 37    | AKT1/BAX/BCL2/CASP3/CCL2/CCDC1/CDK4/CXCL8/EDN1/F3/FN1/ICAM1/L1/IL1/IL6/JUN/MAPK1/MAPK3/Mapk6/Mapk2/Natc1/Nos3/Nox1/Prkca/Prkcbll/Prkcd/Prkce/Prkde/Rela/Sele/Serl/P1/Stat1/Stat3/Tgfb1/Tfnd/Tnf/Vcam1 |
| Lipid and atherosclerosis              | 6.20E-34 | 44    | AKT1/ApoB/Bax/Bcl2/Bcl2l1/Casp3/Casp7/Casp8/Casp9/Ccl2/Cxcl8/Cytc/Cyp1a1/Fos/Gsk3b/Hsp90aa1/Ifng/Ifnar1/Ifngr1/Ifngr2/Mmp1/Mmp3/Mmp9/Natc1/Nfkb1/Nfkb2/Nos3/Nox1/Pparg/Prkca/Rela/Roxa/Sele/Stat3/Tnf/Tp53/Vcam1 |
| Hepatitis B                           | 5.07E-32 | 39    | AKT1/Bax/Bcl2/Birc5/Casp3/Casp6/Casp8/Casp9/Cca2/Cdk2/Cdkn1a/Cdk1/Cure1/Cxcl8/Cytc/E2f2/Fos/Ikbkb/Jun/Mappk1/Mappk3/Mappk5/Myc/Natc1/Nfkb1/Pcam/Prkcb/Raf1/Rbl1/Rela/Sele/Tgfbl/Tfnd/Tp53 |
| Prostate cancer                       | 3.12E-28 | 30    | AKT1/Ah/Bcl2/Casp9/Ccnd1/Cdk2/Cdkn1a/Cure1/E2f1/E2f2/Egr2/Egrb2/Gsk3b/Hsp90aa1/Ikbkb/Mappk1/Mappk3/Mdm2/Mmp2/Mmp3/Nfkb1/Nos3/1p3/Plat/Pten/Raf1/Rbl1/Rela/Sele/Tp53/Vcam1 |
| Fluid shear stress and atherosclerosis | 7.38E-27 | 33    | AKT1/Bcl2/Cav1/Ccl2/Cure1/Edn1/Fos/Gstm1/Hmox1/Hsp90aa1/Ikbkb/Mappk1/Mappk3/Mip3/Mmp5/Mmp9/Nfkb1/Ptgss2/Ptgsc/Rela/Tfnd/Tnf/Vcam1 |
| Kaposi sarcoma-associated herpesvirus infection | 2.32E-25 | 36    | AKT1/Bax/Casp3/Casp8/Casp9/Cnd1/Cdk2/Cdkn1a/Cure1/Cxcl8/Cytc/E2f2/Fos/Gsk3b/Hf1a/Icam1/L1/Il1b/Jun/Mappk1/Mappk3/Mappk5/Myc/Natc1/Nfkb1/Ptgs2/Ptgsc/Rela/Tgfbl/Tfnd/Tp53/Vcam1 |
| Human cytomegalovirus infection        | 4.00E-25 | 38    | AKT1/Bax/Casp3/Casp8/Casp9/Ccl2/Ccdn1/CDK1/CDK4/Cdkn1a/Chuk/Cure1/Cxcl8/Cytc/E2f1/E2f2/Fos/Fosl1/Icam1/Kkbkb/Ilbl/Il6/Jun/Mappk1/Mappk3/Mmp2/Natc1/Nfkb1/Nfkb2/Pkca/Pkcb/Ptgss2/Raf1/Rbl1/Rela/Sele/Tp53/Vcam1 |
| IL-17 signaling pathway                | 1.77E-24 | 27    | AKT1/Casp3/Casp9/Ccl2/Cxcl8/Cxcl10/Fos/Fosl1/Gsk3b/Hsp90aa1/Ikbkb/Ikbkb2/Il1b/Il6/Jun/Mappk1/Mappk3/Mpp6/Myh13/Nos3/Nos2/Ptgss2/Raf1/Rbl1/Rela/Sele/Tfnd/Tnf/Vcam1 |
| Small cell lung cancer                 | 2.16E-23 | 26    | AKT1/Bax/Bcl2/Bcl2l1/Casp3/Casp9/Ccnd1/Cdk2/Cdk4/Cdkn1a/Cure1/Cytc/E2f1/E2f2/Fn1/Ikbkb/Myc/Nos2/Pten/Ptgss2/Rbl1/Rela/Roxa/Tfnd/Tp53/Vap |
| Bladder cancer                         | 3.73E-22 | 19    | Ccd1/Cdk4/Cdkn1a/Cxcl8/E2f1/E2f2/Egr2/Egrb2/Mappk1/Mappk3/Mmp2/Mmp6/Ptgs2/Rela/Sele/Tnf/Vcam1 |
| Human T-cell leukemia virus 1 infection | 2.66E-22 | 35    | AKT1/Bax/Bcl2l1/Ccna2/Ccdn1/Cdk2/Cdk4/Cdkn1a/Chek1/Chek2/Chuk/Cure1/E2f1/E2f2/Fos/Fosl1/Icam1/Kkbkb/Ilb/I6/Jun/Mappk1/Mappk3/Mappk5/Mmp6/Nfkb1/Nfkb2/Pkca/Pkcb/P.dtd/Rela/Tgfbl/Tfnd/Tp53/Vap |
| TNF signaling pathway                  | 3.08E-22 | 27    | AKT1/Casp3/Casp7/Casp9/Ccl2/Cxcl8/Cxcl10/Cure1/Edn1/Fos/Gstn1/Ifng/Ikbkb/Ikbkb2/Ikbkb3/Ilb/I6/Jun/Mappk1/Mappk3/Mappk6/Mmp3/Mmp6/Nfkb2/Ptgss2/Rela/Sele/Tnf/Vcam1 |
| Bladder cancer                         | 3.73E-22 | 19    | Ccd1/Cdk4/Cdkn1a/Cxcl8/E2f1/E2f2/Egr2/Egrb2/Mappk1/Mappk3/Mmp2/Mmp6/Ptgs2/Rela/Sele/Tnf/Vcam1 |
| Cellular senescence                    | 1.42E-21 | 30    | AKT1/Ccna2/Ccnc1/Ccnd1/Cdk1/Cdk2/Cdk4/Cdkn1a/Chek1/Chek2/Cxcl8/Cxcl10/E2f1/E2f2/Gfrpb3/Ilb/I6/Mappk1/Mappk4/Mappk3/Mmp2/Mmyc/Natc1/Nfkb1/Pkcaf/Pten/Rbl1/Rela/Tgfbl/Tfnd/Tp53/Vap |
| Pancreatic cancer                      | 1.54E-21 | 23    | AKT1/Bax/Bcl2l1/Casp9/Ccd1/Cdk1/Cdk4/Cdkn1a/Cure1/E2f1/E2f2/Egr2/Egrb2/Ikbkb/Mappk1/Mappk3/Mappk8/Raf1/Rbl1/Rela/Sele/Tgfb1/Tp53/Vap |
| Endocrine resistance                   | 2.67E-21 | 25    | AKT1/Bax/Bcl2l1/Ccd1/Cdk4/Cdkn1a/E2f1/E2f2/Egr2/Egrb2/Esr1/Esr2/Fos/Jun/Mappk1/Mappk4/Mappk3/Mmp2/Mmp6/Pkca/Pkcb/Raf1/Rbl1/Tap1/Tapp2/Tap3/Vap |
| Proteoglycans in cancer                | 3.87E-21 | 33    | AKT1/Casp3/Casp9/Cdcl1/Cdk4/Cdkn1a/E2f1/E2f2/Fos/Gfrpb3/Ilb/I6/Mappk1/Mappk4/Mappk3/Mmp2/Mmp6/Pkca/Pkcb/Pdk1/Raf1/Rbl1/Rela/Roxa/Stat3/Tgfbl/Tfnd/Tp53/Vap |
| Chemical carcinogenesis - receptor activation | 1.15E-20 | 33    | Ahrk/Akt1/Arb/Birc5/Ccnd1/Cure1/Cyp1a1/Cyp1b1/Cyp2a4a1/E2f1/Egr2/Esr1/Esr2/Fos/Gstn1/Hsp90aa1/Jun/Mappk1/Mappk3/Myc/Pgcr/Ppara/Pkca/Pkrcb/Raf1/Rbl1/Rela/Roxa/Sele/Tgfbl/Tfnd/Tp53/Vap |
| Apoptosis                              | 7.47E-20 | 27    | AKT1/Bax/Birc3/Bcl2l2/Birc5/Casp3/Casp7/Casp8/Casp9/Cchuk/Ctss/Cytc/Fos/Kkbkb/Mappk1/Mappk3/Mappk8/Nfkb1/Nfkb2/Pdk1/Ppar1/Raf1/Rela/Tnf/Tp53/Vap |
| Toxoplasmia                            | 9.37E-20 | 25    | Akt1/Alox5/Bcl2l2/Casp3/Casp8/Casp9/Cchuk/Cytc/Fos/Kkbkb/Ilb/Mappk1/Mappk3/Mappk8/Nfkb1/Nos2/Pkcd2/Rela/Sele/Tgfbl/Tfnd/Tnf/Vap |

Dephosphorylating serine, threonine, and tyrosine. As a negative regulator of MAPK signaling, MAPK1 plays an important role in regulating cell proliferation, growth, and differentiation.[27,28] Through the construction of “active ingredient-target-pathway” networks and topology analysis, the main components of TKD that may affect CRA are quercetin, luteolin, kaempferol, wogonin, baicalein, isorhamnetin, nobiletin, formononetin, hydroxyflavone) is a low molecular weight polyphenol phytochemical, usually in the form of quercetin glycoside compound that has chemopreventive and therapeutic effects on many diseases.[29] Its activity is attributed to anti-oxidation, anti-cancer, and immunity-enhancing effects.[30] Importantly, quercetin is cytotoxic to cancer cells but does not damage healthy cells. Further, quercetin can be used as a chemopreventive and therapeutic agent for a variety of cancers through its role in the inhibition of oncogene expression, cell cycle inhibition, induction of apoptosis. Additionally, it has been shown that the compound has anti-tumor effects by its ability to inhibit cancer cell invasion and metastasis.[31] Pang Linrong et al found that quercetin has an inhibitory effect on the proliferation, invasion, and migration of HSP-27 knocked-down colon cancer SW480 cells.[32] Together, their data indicated that the increase in apoptosis in HSP-27 knockdown SW480 cells and the regulation of
apoptosis via Bcl-2 and Bax gene and protein expression are related. Luteolin is a flavonoid, that is mainly derived from Prunella vulgaris, nudiflora purple bead, dense chrysanthemum, wild chrysanthemum, and other plants. Luteolin has anti-inflammatory, anti-tumor, anti-viral, and anti-oxidation activity. Further, it is hypothesized to have a role in liver protection and the enhancement of immune regulation and other biological activities. Due to its low side effects, this medicine has great clinical potential. Kaempferol is a flavonoid derived from the rhizomes of the ginger herb, kaempferi. Its chemical structure is similar to quercetin and isorhamnetin. Survey data has shown that the ingestion of foods high in kaempferol may reduce the risk of cancer and play a role in tumor prevention. Furthermore, experimental studies have shown that kaempferol can inhibit the growth of malignant tumors through multiple pathways and multiple targets, including tumors related specific to the digestive system. The anti-tumor mechanism of kaempferol involves PI3K/Akt, EGFR, MAPK, Wnt, and other signaling pathways. Specifically, the PI3K/Akt signaling pathway is hypothesized to be the main target of kaempferol. Interestingly, using network pharmacology, a similar finding was observed which indicated that the PI3K/Akt signaling pathway is an important pathway for the treatment of cancer by kaempferol.
In the current study, GO enrichment analysis indicated that the TKD mechanism of action involves multiple BP and molecular functions. Among them, the main BP with the highest correlation include chemical stress responses, oxidative stress responses, responses to reactive oxygen species, drug responses, steroid hormone responses, etc. KEGG pathway enrichment analysis has shown that the TKD mechanism of action in the treatment of CRA is associated with the AGE-RAGE signaling pathway in diabetic complications, lipid metabolism, atherosclerosis, prostate cancer, IL-17 signaling, small cell lung cancer, hepatitis C, and human T-cell leukemia. Many pathways such as those involved in virus-1 infection and TNF signaling are closely related. From the results of both the GO and KEGG enrichment analysis, the effect of TKD on CRA highlights the advantages of traditional Chinese medicine.

5. Conclusion

In summary, this study demonstrated the potential mechanism of TKD in the treatment of preventing colorectal precancerous lesions based on network pharmacology. Our data indicate that quercetin, luteolin, kaempferol, wogonin, wogonin, baicalein, isorhamnetin, nobiletin, nobiletin, and formononetin, etc., affect multiple CRAs. The core targets (AKT1, TP53, MAPK1, MAPK8, JUN, IL6, TNF, STST3, MAPK3, and EGFR) play an important role in CRAs. In addition, the KEGG analysis conducted in this study shows that the intervention of TKD on CRA is related to multiple pathways, including the AGE-RAGE signaling pathway in diabetic complications, lipid metabolism, atherosclerosis, IL-17 signaling, small cell lung cancer, hepatitits-C, and TNF signaling. This study provides an important basis for the prevention of CRC using traditional Chinese medicine and highlights the importance of the further study of TKD.

Acknowledgments

We thank Prof Renjie-Shi, Department of Proctology, Jiangsu Hospital of Traditional Chinese Medicine, who provided guidance for the source of prescriptions and the basis of the previous study.

Author contributions

Data curation: Fang Liu, Bo Cao. Formal analysis: Yukun Dong. Investigation: Guoxiong Liu. Validation: Donglin Ren, Dan Su. Writing-original draft: Fang Liu. Editing: Heng Zhang. Qi Zou. All authors reviewed and approved the final manuscript. Conceptualization: Yuming Yao. Data curation: Yuming Yao. Formal analysis: Xiang Zhu, Yuming Yao. Methodology: Xiang Zhu. Software: Xiang Zhu.
Supervision: Jiayi Jiang, Weixin Liu
Visualization: Han Jiang

References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–33.
[2] Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019;16:713–32.
[3] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.
[4] Zhang S. Analysis of hyperlipidemia in patients with colorectal polyp. China General Clin. 2015;31:337–40.
[5] Liu L, Zhang X, Wang R, et al. The relationship between colorectal polyp and blood lipid levels. Progress Modern Biomed Adv. 2016;25:4979–83.
[6] Wang J, Cheng H. Research on the application of cancer virulence and pathogenesis theory in tumor prevention and treatment based on the idea of “preventing disease”. J Tradit Chin Med. 2018;59:1014–6.
[7] Fang L. Clinical and basic research of “clinical and basic research on prevention and treatment of colorectal adenoma with "tenghi anti-tumor prescription” based on the theory of "strengthening the body and expelling pathogenic factors” [D]. Nanjing University of Chinese Medicine. 2019.
[8] Ru J, Li P, Wang J, et al. TCMP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;6:13.
[9] UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 2019;47:D506–15.
[10] Safran M, Dalah I, Alexander J, et al. GeneCards Version 3: the human gene integrator. Database (Oxford). 2010;2010:baq020.
[11] Amberger JS, Bocchini CA, Schiettecatte F, et al. OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. Nucleic Acids Res. 2015;43(Database issue):D789–98.
[12] NCBI Resource Coordinators. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2018;46:D12–D13.
[13] Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607–13.
[14] Doncheva NT, Morris JH, Gorodkin J, et al. Cytoscape StringApp: network analysis and visualization of proteomics data. J Proteome Res. 2018;17:623–32.
[15] Sun C, Yuan Q, Wu D, et al. Identification of core genes and outcome in gastric cancer using bioinformatics analysis. Oncotarget. 2017;8:70271–80.
[16] Roncucci L, Mariani F. Prevention of colorectal cancer: How many tools do we have in our basket? Eur J Intern Med. 2015;26:752–6.
[17] Zhang L. Study on the chemical constituents and biological activity of the root of Rhododendron chinensis [D]. Shaanxi: Northwest A&F University. 2015. (in Chinese with English abstract).
[18] Zhao C, Peng L. Effects of ethanol extracts from the roots of Cinnamomum tenuiloba on the proliferation and invasion of A549 cells. Chin J Clin Pharmacol. 2021;37:993–6.
[19] Huorong Y, Huiling Y, Yin C, et al. Effects of n-butanol extracts from the roots of Cinnamomum japonicum on autophagy and apoptosis of breast cancer cells by inhibiting PI3K/Akt/mTOR pathway. Chin Clin Oncol. 2021;26:104–9.
[20] Yang Z, Yang F, Zhang W. Research progress on effective components and anti-tumor effects of root of Tengli(Actinidia Chinensis). Chin Arch Trad Chin Med. 2021;39:204–8.
[21] Yan-qiong Z, Xia M, Qiu-yan G, et al. Network pharmacology-based approaches capture essence of Chinese herbal medicines. Chin Herbal Med. 2016;02:107–16.
[22] Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med. 2013;11:110–20.
[23] Zhang R, Zhu X, Bai H, et al. Network pharmacology databases for traditional Chinese medicine: review and assessment. Front Pharmacol. 2019;10:123.
[24] Shariati M, Meric-Bernstam F. Targeting AKT for cancer therapy. Expert Opin Investig Drugs. 2019;28:977–88.
[25] Riggio M, Perrone MC, Polo ML, et al. AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins. Sci Rep. 2017;7:44244.
[26] Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333–9.
[27] Bashanfer SA, Saleem M, Heidenreich O, et al. Disruption of MAPK1 expression in the ERK signalling pathway and the RUNX1-RUNX1T1 fusion gene attenuate the differentiation and proliferation and induces the growth arrest in t(8;21) leukaeemia cells. Oncol Rep. 2019;41:2027–40.
[28] Yang Y, Li XJ, Li P, et al. MicroRNA-145 regulates the proliferation, migration and invasion of human primary colon adenocarcinoma cells by targeting MAPK1. Int J Mol Med. 2018;42:3171–80.
[29] Sharma A, Kasyhap D, Sak K, et al. Therapeutic charm of quercetin and its derivatives: a review of research and patents. Pharm Pat Anal. 2018;7:15–32.
[30] Reyes-Farias M, Carrasco-Pozo C. The anti-cancer effect of quercetin: molecular implications in cancer metabolism. Int J Mol Sci. 2019;20:3177.
[31] Tang SM, Deng XT, Zhou J, et al. Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects. Biomed Pharmacother. 2020;121:109604.
[32] Yang Y, Chen J, Jinger L, et al. Effect of Quercetin on proliferation, migration and invasion in colon cancer SW480 cells with HSP-27 knockdown and its mechanism. J Chin Med Mater. 2021;44:1470–6.
[33] Yang D, Yao X, Hu Y. Simultaneous determination of the contents of 4 compounds in S. mongolica from different origins by HPLC. Chin J Modern Appl Pharm. 2020;37:921–5.
[34] Yan J, Wang Q, Zheng X, et al. Luteolin enhances TFE-related apoptosis-inducing ligand's anticancer activity in a lung cancer xenograft mouse model. Biochem Biophys Res Commun. 2012;417:842–6.
[35] Chen Z, Zhang B, Gao E, et al. Modulation of G2/M cell cycle arrest and apoptosis by luteolin in human colon cancer cells and xenografts. Oncol Lett. 2018;15:1599–65.
[36] Xiao Y, Xin L, Li L, et al. Quercetin and kaempferol increase the intracellular concentration of flavonoids and breast cancer risk among Chinese women. Eur J Nutr. 2021;60:1347–62.
[37] Wang L, Dai ZS. The effect of kaempferol on PARP1 and P53 genes expression in gastric cancer cells. Jiyinzuxue Yu Yingyong Shengwuxue (Genomics and Applied Biology). 2020;39:1270–4.
[38] Wang BJ, Dai ZS. The effect of kaempferol for the treatment of gastric cancer based on network pharmacology. Biomed Res Int. 2020;2020:15891016–11.